Posaconazole oral suspension

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Leukemia, Myelocytic, AcuteMycosesMyelodysplastic SyndromesNeutropenia

Phase 2

PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)

CompletedNCT00034671

Merck Sharp & Dohme LLCMycoses

Start: 2001-01-31End: 2002-03-31Updated: 2015-12-31

Phase 3

Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease

CompletedNCT00034645

Merck Sharp & Dohme LLCMycoses

Start: 1999-01-31End: 2003-02-28Updated: 2017-03-10

Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)

CompletedNCT00034632

Merck Sharp & Dohme LLCMycoses

Start: 2001-04-30End: 2007-03-31Updated: 2017-03-10

Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)

CompletedNCT00044486

Merck Sharp & Dohme LLCLeukemia, Myelocytic, Acute, Myelodysplastic Syndromes, Neutropenia

Start: 2002-07-31End: 2005-04-30Updated: 2017-03-10

Related Papers

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

2007-01-011211 citations

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

2007-01-01878 citations